Swiss pharmaceutical manufacturer Lonza Group AG is in advanced talks to acquire Capsugel, a U.S. maker of capsule products and other drug delivery systems, for more than $5 billion, according to people familiar with the matter. The deal would come as Lonza seeks to boost its life sciences capabilities and produce a wider range of molecules used in active pharmaceutical ingredients and drug delivery. It held unsuccessful talks to acquire U.S. drug delivery technology company Catalent Inc earlier this year.
See the original post:
Exclusive: Lonza in talks to buy Capsugel for more than $5 billion – sources